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ABSTRACT
Objective Although fetal growth restriction (FGR) is well
known to be associated with adverse outcomes for the
mother and offspring, effective interventions for the
management of FGR are yet to be established. Trials
reporting interventions for the prevention and treatment
of FGR may be limited by heterogeneity in the underlying
pathophysiology. The aim of this study was to conduct
a systematic review of outcomes reported in randomized
controlled trials (RCTs) assessing interventions for the
prevention or treatment of FGR, in order to identify
and categorize the variation in outcome reporting.
Methods MEDLINE, EMBASE and The Cochrane
Library were searched from inception until August
2018 for RCTs investigating therapies for the preven-
tion and treatment of FGR. Studies were assessed sys-
tematically and data on outcomes that were reported
in the included studies were extracted and categorized.
The methodological quality of the included studies was
assessed using the Jadad score.
Results The search identified 2609 citations, of which
153 were selected for full-text review and 72 studies (68
trials) were included in the final analysis. There were 44
trials relating to the prevention of FGR and 24 trials
investigating interventions for the treatment of FGR. The
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mean Jadad score of all studies was 3.07, and only nine
of them received a score of 5. We identified 238 outcomes
across the included studies. The most commonly reported
were birth weight (88.2%), gestational age at birth
(72.1%) and small-for-gestational age (67.6%). Few
studies reported on any measure of neonatal morbidity
(27.9%), while adverse effects of the interventions were
reported in only 17.6% of trials.
Conclusions There is significant variation in outcome
reporting across RCTs of therapies for the prevention
and treatment of FGR. The clinical applicability of future
research would be enhanced by the development of a core
outcome set for use in future trials. Copyright ! 2018
ISUOG. Published by John Wiley & Sons Ltd.
INTRODUCTION
The failure of a fetus to reach its growth potential can
be attributed to many different pathological processes
such as infection, placental dysfunction or maternal
disease or malnutrition. Although there are inconsistencies
in classification and diagnosis, between one-quarter
and half of all stillbirths are associated with fetal
growth restriction (FGR), and a significant proportion
of babies suffering birth asphyxia are similarly growth
restricted1–3. Apart from the risk of perinatal morbidity
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and mortality4,5, there is a long-term impact of growth
restriction on childhood neurological development and
metabolic and cardiovascular disorders6,7, which is
thought to be, at least in part, due to epigenetic changes
induced by the pathological intrauterine environment in
addition to the direct pathological effects of altered blood
flow and intrauterine malnutrition. Despite the clinical
implications of FGR, the majority of affected infants are
not detected antenatally3, and, as yet, no therapeutic
interventions have been demonstrated to reverse or
ameliorate the effects of FGR.
Research on FGR has focused primarily on improving
antenatal detection and then on determining the optimal
timing of delivery in order to balance the risks of
intrauterine demise and iatrogenic preterm delivery.
Studies investigating interventions for the prevention
and treatment of FGR have reported a wide variety of
outcomes6, and have not always included outcomes that
relate to harm from the interventions8. Heterogeneity in
outcomes and outcome measures reported across studies
hinders the synthesis of findings, while the rarity of
outcomes such as stillbirth and neonatal death leads
to many studies being underpowered to answer the
clinical question of interest. The extent of heterogeneity
of outcomes reported in FGR intervention studies has not
been formally assessed.
The aim of this study was to conduct a systematic
evaluation of outcomes reported in randomized controlled
trials (RCTs) assessing the effects of interventions for the
prevention or treatment of FGR in order to identify and
categorize the variation in outcome reporting.
METHODS
The protocol for this systematic review was
registered on PROSPERO (registration number:
CRD42018074910). We followed the reporting guide-
lines for meta-analyses and systematic reviews of RCTs,
as outlined by the PRISMA statement9. EMBASE,
MEDLINE and The Cochrane Library including The
Cochrane Database of Systematic Reviews (CDSR),
Database of Abstracts of Reviews of Effects (DARE)
and The Cochrane Central Register of Controlled Trials
(CENTRAL) were searched from inception to August
2018 for RCTs evaluating any potential intervention for
the prevention or treatment of FGR (Table S1). Medical
Subject Headings (MeSH) including FGR, fetal therapies,
prenatal care and pregnancy complications were used,
and additional records were identified by manually
searching reference lists; the search was restricted to
the English language. We included RCTs in which
interventions for the prevention or treatment of FGR
were either the primary or secondary outcome. Cohort
and case–control studies, case series, case reports and
systematic reviews were excluded. We accepted the
authors’ definition of FGR.
At least two researchers (H.K., L.S. or R.T.) indepen-
dently reviewed each potentially relevant record based
on the title and abstract. Full texts were retrieved
for each potentially relevant citation and two authors
independently reviewed the full text of each selected study
to assess its eligibility for inclusion. Discrepancies between
the authors were resolved by discussion.
Using a standardized data extraction form, at least two
researchers (F.S., L.S. or R.T.) reviewed each included
study and independently extracted trial characteristics
including number of participants, funding sources,
country of study, definition of FGR, intervention
evaluated and outcomes. The methodological quality of
the included studies was assessed by each of the two
reviewers independently using the Jadad score, which
awards 2 points for adequate randomization, 2 for
adequate blinding and 1 for follow-up of all randomized
patients10. Discordant scores were resolved by consensus.
A comprehensive inventory of all outcomes was
developed and initially organized into four broad
categories: fetal outcomes, maternal outcomes, neonatal
outcomes and childhood outcomes.
RESULTS
A total of 2605 citations were identified through
the literature search and an additional four records
by manual searching. After exclusion of 2456 abstracts,
153 papers were selected for full-text review. Of these,
81 papers were excluded, the majority because they
were a non-randomized study, were not in English
or were a duplicate of an already included study
(Table S2). Seventy-two reports from 68 trials met the
inclusion criteria and were included in the systematic
review (Figure 1). Forty-four trials reported on potential
interventions for the prevention of FGR11–54 and 24
(29 studies) reported on interventions for the treatment
of pregnancies affected by FGR30,55–82. Five papers
reporting outcomes from the DIGITAT trial78–82 and
two from the TRUFFLE trial60,61 were included. One
paper included two separate trials addressing both
points30. In total, 44 trials (45 062 participants) reporting
interventions for the prevention of FGR and 24 trials
(3357 participants) evaluating antenatal treatments for
FGR were included (Figure 1).
All included studies were RCTs. The interventions
evaluated for the prevention of FGR included admin-
istration of aspirin (n = 9), diet or exercise advice (n = 3),
nutritional supplementation (n = 18), psychosocial inter-
vention (n = 5), low-molecular-weight heparin (n = 2),
hospital admission (n = 1), intravenous immunoglobulin
(n = 1) and management of maternal medical conditions
such as hypertension, heroin addiction and periodontal
disease (n = 5). The interventions evaluated for the treat-
ment of FGR included aspirin (n = 4), l-arginine (n = 4),
fetal nutrition (n = 1), fish oil/omega-3 (n = 2), plasma
volume expansion (n = 1), hospital admission (n = 2),
intensive antenatal monitoring (n = 2), induction of labor
(n = 2), nitric oxide donors (n = 1), low-molecular-weight
heparin (n = 2), sildenafil (n = 1), dydrogesterone (n = 1)
and maternal hyperoxygenation (n = 1). The characteris-
tics of the included studies evaluating interventions for the
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Potentially relevant citations identi!ed in
MEDLINE, EMBASE and
The Cochrane Library including
The Cochrane Database of
Systematic Reviews (CDSR),
Database of Abstracts of Reviews of Effects
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Figure 1 Flowchart illustrating selection and inclusion in this
systematic review of randomized controlled trials (RCTs)
evaluating potential interventions for prevention or treatment of
fetal growth restriction (FGR). *Some articles reported on
outcomes from same trial.
prevention and treatment of FGR are outlined in Tables 1
and 2, respectively. Twenty-two studies compared the
intervention with placebo, 23 with an alternative treat-
ment and 23 with routine care only. Forty-six studies were
performed in high-resource settings (determined by the
human development index of the study location) and 18 in
low-resource settings, with the remainder including both
high- and low-resource settings. Studies evaluating the
prevention of FGR included more participants (median,
870 (interquartile range (IQR), 219–1297)) than did stud-
ies investigating treatment (median, 69 (IQR, 49–138)).
Fifty-seven trials declared funding sources, one reported
no funding and 10 made no declaration. Nine included
studies received a Jadad score of 5, while the mean Jadad
score of all studies was 3.07 (Table S3).
The included studies reported on 238 outcomes
(Table S4). These were maternal (44.1%), fetal (11.8%),
neonatal or infant (37.4%) and relating to resource
usage (6.7%). The most commonly reported outcomes
were birth weight (88.2%), gestational age at delivery
(72.1%), small-for-gestational age (SGA) (67.6%), still-
birth (60.3%) and mode of delivery (55.9%) (Table S4).
When mortality outcomes were reported, they were not
always defined clearly. Of those studies reporting still-
birth, perinatal or neonatal death, only 20%, 17% and
32%, respectively, provided the temporal definitions of
these terms. When stillbirth was defined, the term was
used heterogeneously to include either all fetal loss or
intrauterine demise after 20, 22, 24 and 28 weeks. Early
and late neonatal deaths were reported separately in three
studies, although there was no temporal definition given
in the majority of the studies reporting neonatal death.
Of the 105 maternal outcomes reported, these were
frequently related to an underlying or comorbid medical
condition (32/105 (30.5%) outcomes), and only rarely
to potential adverse effects of the intervention (5/105
outcomes, reported in 12/68 (17.6%) of the included
trials). The most commonly reported maternal outcomes
were mode of delivery (38/68 (55.9%) trials) and the
development of hypertensive disorders of pregnancy
(HDP) and their complications. Nineteen (27.9%) of
the included trials theorized that a reduction in FGR
would be brought about by the intervention reducing
the incidence and/or severity of HDP. One trial reported
maternal self-reported outcomes of anxiety and pain at
6 months postpartum80, but no other studies evaluated
long-term maternal outcomes.
Fetal outcomes other than stillbirth and miscarriage
were infrequently reported in prevention trials (9/44
(20.5%)), which tended to have a larger sample size
and focus on outcomes measured at birth. Ultrasound
measurements (Doppler, biometry and amniotic fluid
assessments) were the most commonly reported fetal
outcomes (15/28 (53.6%) fetal outcomes) and were
assessed in 13/24 (54.2%) treatment trials and 7/44
(15.9%) prevention trials. Investigators considered
Doppler assessment of the umbilical, uterine and fetal
middle cerebral arteries, ductus venosus and the thoracic
aorta, and fetal biometry. Additional fetal testing via fetal
blood sampling in the umbilical cord or scalp in labor
was reported in two studies.
When considering perinatal outcomes, birth weight and
gestational age at delivery were reported consistently
across most trials (in 88.2% and 72.1% of trials,
respectively), although the presentation varied. Admission
to the neonatal intensive care unit (NICU) (36/68
(52.9%)), Apgar score (29/68 (42.6%)) and umbilical
cord blood-gas analysis (10/68 (14.7%)) were commonly
reported as outcomes relating to fetal status at birth.
Other measures of fetal hypoxia reported included the
need for neonatal resuscitation, birth trauma and birth
asphyxia. Investigators more frequently reported neonatal
death (28 trials) than perinatal mortality (23 trials).
Many studies did not report on neonatal morbidity
beyond 28 days postpartum. Only 19 (27.9%) of the
included trials reported on any neonatal morbidity
outcome, and trials of treatment interventions were
more likely to report on neonatal morbidity than were
prevention trials. Six (13.6%) prevention trials and 13
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(n) Definition of FGR Intervention Primary outcome
Ashorn (2015)11 Malawi 4 1391 BW < 10th centile Lipid-based nutrition
supplementation
BW and length
Ali (2018)12 Saudi Arabia 3 179 ND Vitamin D (4000 units) PE
Bar (1997)23 Israel 5 87 ND Aspirin (60 mg) Fetal circulation parameters
Binder (2008)34 Czech
Republic




Bhutta (2009)45 Pakistan 3 2378 ND Multiple micronutrients Maternal health and birth
outcomes









Number of episodes of
severe HTN, number of
women with severe HTN
or adverse fetal outcomes
Chan (2009)52 Hong Kong 4 1164 BW < 10th centile Ferrous sulfate Risk of GDM
Crowther (1992)53 Zimbabwe 3 218 ND Hospital admission Development of severe
HTN, proteinuria, BW,
NICU admission and LoS
Cruickshank (1992)54 UK 3 114 BW < 10th centile Labetalol BW < 10th centile
Donovan (1977)13 UK 1 1202 ND Smoking cessation FGR
ECPPA (1996)14 Brazil 4 1009 BW < 3rd centile Aspirin (60 mg) PE
Fawzi (1998)15 Tanzania 4 1075 BW < 2500 g Multivitamin
supplementation
Progression of HIV-1, birth
outcomes





Groom (2017)17 Multinational 3 156 BW < 5th centile LMWH PE, SGA




GA at delivery, development
of PE, APH or SGA
Hossain (2014)19 Pakistan 1 193 BW < 2500 g Vitamin D Not specified
Janmohamed (2016)20 Cambodia 3 547 BW < 10th centile Dietary supplementation BW and length
Kokanali (2014)21 Turkey 1 295 BW < 10th centile Dietary advice Maternal and perinatal
morbidity
Kumwenda (2002)22 Malawi 5 697 BW < 2500 g Vitamin A Birth outcome




Lagendijk (2018)25 Netherlands 3 5296 BW < 10th centile Triaged antenatal care PTB, SGA
Levine (1997)26 USA 4 4589 BW < 10th centile Calcium PE, SGA
Metcoff (1985)27 USA 2 471 BW < 3150 g Food supplementation BW
Moses (2014)28 Australia 3 691 BW < 10th centile Low GI diet Fetal growth centile and PI
Newnham (2009)29 Australia 3 1082 BW < 10th centile Periodontal disease
management
PTB, FGR, PE
Olsen (2000)30 Europe 4 280 BW < 10th centile Fish oil Recurrence of FGR
Onwude (1995)31 UK 5 233 BW < 3rd and < 10th
centiles
Fish oil PE, PIH, asymmetric growth
restriction
Parazzini (1993)32 Italy 3 1032 BW < 10th centile Aspirin (50 mg) PIH, FGR
Poston (2015)33 UK 3 1555 BW < 10th customized
centile
Behavioral intervention GDM, LGA
Rakhshani (2012)35 India 5 93 Fetus unable to reach
required growth
potential for GA
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(n) Definition of FGR Intervention Primary outcome
Ramakrishnan (2003)36 Mexico 4 873 BW < 10th centile Multiple micronutrients BW and length
Rodger (2014)37 Multinational 3 289 BW < 10th centile LMWH Major VTE, severe PE,
SGA, pregnancy loss
Rolnik (2017)38 UK 5 1776 BW < 5th centile Aspirin (150 mg after
screening)
Preterm PE
Roth (2018)39 Bangladesh 5 1300 BW < 10th centile Vitamin D Infant length-for-age
Z-score at 1 year
Siega-Riz (2006)40 USA 5 867 BW < 10th centile Ferrous sulfate Anemia
Stanescu (2018)41 Romania 3 150 EFW < 10th centile Aspirin (150 mg) FGR
Steketee (1996)42 Malawi 0 1766 BW < 2500 g
and > 37 weeks
Mefloquine Low BW
Subramanian (2012)43 USA 3 1025 ND Targeted antenatal care Not specified
Sureau (1991)44 France 2 478 ND Aspirin and dipyridamole FGR, IUD, abruption
Toe (2015)46 Burkina Faso 2 1296 BW < 10th centile Lipid-based nutrition
supplements
BW, birth length, FGR, PTB
Vainio (2002)47 Finland 3 86 BW < 10th centile Aspirin (0.5 mg/kg) PIH, PE, FGR, duration of
pregnancy, BW
Villar (1992)48 Multinational 2 2235 BW < 10th centile Psychosocial support FGR
Villar (2009)49 Multinational 3 1365 BW < 10th centile Vitamins C and E PE, low BW, SGA,
perinatal death
Only first author of each study is given. APH, antepartum hemorrhage; BW, birth weight; EFW, estimated fetal weight; GA, gestational age;
GDM, gestational diabetes mellitus; GI, glycemic index; HDP, hypertensive disorders of pregnancy; HIV, human immunodeficiency virus;
HTN, hypertension; IUD, intrauterine demise; LGA, large-for-gestational age; LMWH, low-molecular-weight heparin; LoS, length of stay;
NAS, neonatal abstinence syndrome; ND, not defined; NICU, neonatal intensive care unit; PE, pre-eclampsia; PI, pulsatility index; PIH,
pregnancy-induced hypertension; PTB, preterm birth; SGA, small-for-gestational age; SR, slow release; VTE, venous thromboembolism.
(54.2%) treatment trials reported any neonatal morbidity
outcomes. The most frequently reported items included
intraventricular hemorrhage and other neurological
morbidity, respiratory compromise (including respiratory
distress syndrome, bronchopulmonary dysplasia, chronic
lung disease and need for ventilation, continuous positive
airway pressure and oxygen), necrotizing enterocolitis
and sepsis. Four trials used a score (MAIN (morbidity
assessment index for newborns), CRIB (clinical risk index
for babies) or the Prechtl neonatal neurological exam
score) to quantify the neonatal overall or neurological
morbidity. Three studies17,61,65 reported a composite
outcome for neonatal morbidity, including neurological,
respiratory and gastrointestinal morbidity, with two
additionally including retinopathy of prematurity or
sepsis. One study61 reported the composite of perinatal
death and neonatal morbidity. Treatment studies were
more likely to report neonatal morbidity, while both
prevention and treatment studies published after 2000
were more likely to report neonatal morbidity outcomes.
Seven percent of prevention trials published before 2000
compared with 33.3% published after 2000 reported any
neonatal morbidity outcome, while the respective rate
for treatments trials was 42.8% vs 58.8%. Only five
trials reported on longer-term follow-up (up to 2 years) of
included infants and only three assessed motor, behavioral
and cognitive development.
The variation in outcome reporting across the 30 largest
prevention trials and the 24 included treatment trials is
illustrated in Figures 2 and 3, respectively.
DISCUSSION
Summary of main findings
We have identified a wide range of, and significant
variation in, maternal and offspring outcomes reported
in trials evaluating the effects of interventions for the
prevention and treatment of FGR. Most reported birth
weight, gestational age at delivery and SGA whereas only
approximately half reported stillbirth, mode of delivery,
admission to the NICU and preterm delivery. Only a
quarter of trials reported important neonatal morbidity
outcomes, including respiratory distress syndrome, necro-
tizing enterocolitis and neurological complications. Three
studies addressed the problem of low incidence of impor-
tant perinatal outcomes using a composite outcome, but,
in each case, the composite differed sufficiently between
trials to preclude direct comparison. Few trials reported
outcomes related to potential harm from the interventions
considered.
Strengths and limitations
This study provides a comprehensive overview of out-
comes evaluated by investigators assessing interventions
for the prevention or treatment of FGR. It is, how-
ever, difficult to speculate why specific outcomes were
selected in each study; they are likely to reflect areas
of clinical or research interest of the individuals involved
in the study design, which, in turn, may be influenced
by the medical, societal, cultural or governmental impor-
tance given to such interventions. When considering
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(n) Definition of FGR Intervention Primary outcome
Ali (2018)55 Egypt 3 60 AC < 2 SD below mean
and HC:AC ratio
increased
Aspirin Change in EFW
Ali (2017)66 Egypt 3 80 AC < 2 SD below mean
and HC:AC ratio
increased
Omega 3 Change in EFW




GA at delivery, mode of
delivery, NICU LoS
Battaglia (1994)77 Italy 2 38 AC < 10th centile Hyperoxygenation Not specified
Cabero (1988)56 Spain 1 98 > 2-week discrepancy
between menstrual
and ultrasound dates
Hospital admission Not specified
Di Iorio (2002)57 Italy 2 20 BPD < 10th centile and
AC < 5th centile and
reduced growth
velocity





Netherlands 4 650 AC < 10th or
EFW < 10th with or
without reduced
growth velocity
Induction of labor Composite of death before
discharge, 5-min Apgar
score < 7, cord arterial
pH < 7.05, NICU
admission
Ganzevoort (2005)58 Netherlands 3 216 EFW < 10th centile or




Hansen (2018)59 Denmark 3 53 EFW < 2.3rd centile LMWH BW, fetal growth rate
McCowan (1999)62 Australia 4 65 AC < 10th centile and
UA-PI > 95th centile
Aspirin BW
Monincx (1997)63 Netherlands 3 150 ND Hospital admission Neurological score
Newnham (1995)64 Australia 4 51 AC < 10th centile and
UA-PI > 95th centile
Aspirin (100 mg) BW
Olsen (2000)30 Europe 4 280 ND Fish oil BW
Sharp (2018)65 UK 5 135 EFW or AC < 10th
centile and AREDF
in UA
Sildenafil Time to delivery
Sieroszewski
(2004)67
Poland 1 108 EFW < 10th centile l-arginine Change in EFW
Singh (2015)68 India 1 60 EFW < 10th centile l-arginine Neonatal outcome
Tchirikov (2017)69 Germany 3 14 EFW < 5th centile and




Trudinger (1988)70 Australia 4 46 UA S/D ratio > 95th
centile




Multinational 3 503 AC < 10th centile and
UA-PI > 95th centile
DV Doppler
monitoring






proven sepsis or NEC
van den Hove
(2006)71
Netherlands 3 33 AC < 10th centile or
reduced growth
velocity
Induction of labor Obstetric intervention,
neonatal outcome
Winer (2009)72 France 4 43 AC < 3rd centile with
abnormal UtA
Doppler
l-arginine BW, neonatal morbidity
Continued over.
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(n) Definition of FGR Intervention Primary outcome




Yu (2010)74 China 1 73 SFH < 10th centile or
HC:AC ratio < 10th




Zarean (2018)75 Iran 4 89 EFW < 10th centile Dydrogesterone Fetal weight, MCA- and
UtA-RI
Only first author of each study is given. AC, abdominal circumference; AM, adrenomedullin; AREDF, absent or reversed end-diastolic flow;
BPD, biparietal diameter; BW, birth weight; cPVL, cystic periventricular leukomalacia; DV, ductus venosus; EFW, estimated fetal weight;
FL, femur length; GA, gestational age; HC, head circumference; LMWH, low-molecular-weight heparin; LoS, length of stay; MCA, middle
cerebral artery; ND, not defined; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; NO, nitric oxide; NO2, nitrite; NO3,
nitrate; PI, pulsatility index; RI, resistance index; S/D, systolic/diastolic; SFH, symphysiofundal height; UA, umbilical artery; UtA, uterine
artery.
novel interventions for the prevention and treatment
of FGR, most trials were not funded by industry. The
included trials were from both high- and low-resource
settings and from a diverse range of international centers,
which ensures inclusion of the maximum range of out-
comes. The identification of trials and data extraction
were systematically conducted by two reviewers and in
line with the recommendations of the COMET initiative
guidelines to maintain the highest standards of research
quality83.
None of the included trials reported the inclusion
of patient or family representatives in the choice of
outcomes measured and reported. It is possible that
additional outcomes would be identified as important or
given greater weight by stakeholders other than clinicians.
Exploring this point would require additional qualitative
research. Furthermore, interventions for the prevention or
treatment of FGR are often directed at maternal medical
conditions associated with FGR, and maternal outcomes
related to these conditions (hypertension, thrombosis and
infection) are therefore reported frequently in the included
trials, but might not be key outcomes in the study of
FGR in other contexts. Equally, trials reporting FGR
as a secondary outcome may have been less likely to
have been identified from the targeted literature search
we performed, but the key outcome of interest in this
review was FGR, and broadening the search would have
increased the number of outcomes not related directly to
FGR and irrelevant to the development of a core outcome
set (COS). The key maternal condition most closely
associated with FGR is pre-eclampsia, and variation in
outcome reporting in pre-eclampsia trials was investigated
in depth by the iHOPE collaboration84–86. The majority
of outcomes identified in the included studies were also
identified in our review, and of those not specified in the
trials included in this study, most were maternal outcomes
relating to the complications of severe pre-eclampsia,
such as maternal cardiac failure. These are clearly
important endpoints for trials investigating pre-eclampsia,
but are not likely to be relevant to trials on FGR.
Although there is a pathophysiological overlap between
pre-eclampsia and FGR, these are two separate disorders
and the outcomes likely to be important to researchers,
patients and stakeholders are not and should not be
identical.
Clinical and research implications
As described previously in studies investigating
outcome reporting in other obstetric conditions includ-
ing pre-eclampsia86 and twin-to-twin transfusion
syndrome87, we have demonstrated significant variation
in outcome reporting in trials of interventions for FGR.
With the establishment of national and international
initiatives aimed at reducing stillbirths and perinatal
mortality88 and improving child health, addressing FGR
is now a key clinical priority. Interventions to prevent or
treat FGR have the potential to improve fetal, neonatal
and child health and should be evaluated in the context
of potential harm and benefits to the mother and baby.
There is a clear need for robust investigation of new
interventions for the prevention and treatment of FGR,
but the observed variation in outcome reporting is a
factor limiting the comparison of studies on FGR, and
thus their clinical applicability.
Identification of high-value interventions for the
prediction and treatment of FGR might be improved
by the development of a COS, which is the minimum
set of outcomes that authors should report on in all
trials evaluating the effects of interventions for a given
condition/field. COSs are developed with the idea of
reducing waste in research by selecting those outcomes
that are most relevant to all stakeholders and are
applicable in most research settings. The use of a
COS would reduce variation in outcome reporting and
promote the routine collection of such data. Standardized
reporting of outcomes would increase generalizability,
allow for meaningful pooled analysis and be of greater
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relevance to clinicians and stakeholders. Development
of COSs within women’s health is recommended by
‘The CoRe Outcomes in Women’s and Newborn health
(CROWN) initiative’ (www.crown-initiative.org), which
seeks to harmonize outcome reporting in women’s health
research. It is important to add that a COS is not the
only requirement for optimal comparability of studies.
As shown in this review, if outcomes are measured with
different definitions, comparability is also compromised.
Standardization of how to measure these outcomes is also
vital. The findings of this review could be taken forward to
form the basis of the development of a COS via discussion
with clinical and patient stakeholders. The outcomes
identified as frequently reported by researchers in this
review should form the starting point for a Delphi process
to establish consensus on the key outcomes to be included
in a COS for FGR, with attention given subsequently
to standardizing the definition and measurement of
these core outcomes. The involvement of researchers
in this process and the leadership of major journals in
committing to the CROWN initiative are key to ensure
uptake of the COS in future studies, and ultimately
























































































































































































































































































































Figure 2 Reporting of maternal, fetal, neonatal and childhood outcomes in 30 largest randomized controlled trials investigating
interventions for prevention of fetal growth restriction included in review.
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Figure 3 Reporting of maternal, fetal, neonatal and childhood outcomes in 24 randomized controlled trials investigating interventions for
treatment of fetal growth restriction included in review.
our ability as a research community to prevent and
treat FGR.
Conclusions
Significant variation exists in outcome reporting in RCTs
investigating interventions for the prevention and treat-
ment of FGR. FGR is a key target area for improving
fetal and neonatal health. Identification of key outcomes,
and a move to standardized reporting, are urgently needed
to facilitate high-quality investigation of novel interven-
tions and minimize research waste.
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on pregnancy outcomes in women with one elevated oral glucose tolerance test value.
Ginekol Pol 2014; 85: 748–753.
22. Kumwenda N, Miotti PG, Taha TE, Broadhead R, Biggar RJ, Jackson JB, Melikian G,
Semba R. Antenatal vitamin A supplementation increases birth weight and decreases
anemia among infants born to human immunodeficiency virus-infected women in
Malawi. Clin Infect Dis 2002; 35: 618–624.
23. Bar J, Hod M, Pardo J, Fisch B, Rabinerson D, Kaplan B, Meizner I. Effect on
fetal circulation of low-dose aspirin for prevention and treatment of pre-eclampsia
and intrauterine growth restriction: Doppler flow study. Ultrasound Obstet Gynecol
1997; 9: 262–265.
24. Kupka R, Mugusi F, Aboud S, Msamanga G, Finkelstein J, Spiegelman D, Fawzi W.
Randomized, double-blind, placebo-controlled trial of selenium supplements among
HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes.
Am J Clin Nutr 2008; 87: 1802–1808.
25. Lagendijk J, Vos AA, Bertens LCM, Denktas S, Bonsel GJ, Steyerberg EW, Been JV,
Steegers EAP. Antenatal non-medical risk assessment and care pathways to improve
pregnancy outcomes: a cluster randomised controlled trial. Eur J Epidemiol 2018;
33: 577–589.
26. Levine R, Hauth J, Curet L, Sibai B, Catalano P, Morris C, DerSimonian R, Esterlitz J,
Raymond E, Bild D, Clemens J, Cutler J. Trial of calcium to prevent pre-eclampsia.
N Engl J Med 1997; 337: 69–76.
27. Metcoff J, Costiloe P, Crosby WM, Dutta S, Sandstead HH, Milne D, Bodwell CE,
Majors S. Effect of food supplementation (WIC) during pregnancy on birthweight.
Am J Clin Nutr 1985; 41: 933–947.
28. Moses RG, Casey SA, Quinn EG, Cleary JM, Tapsell LC, Milosavljevic M, Petocz P,
Brand-Miller JC. Pregnancy and Glycemic Index Outcomes study: effects of low
glycemic index compared with conventional dietary advice on selected pregnancy
outcomes. Am J Clin Nutr 2014; 99: 517–523.
29. Newnham JP, Newnham IA, Ball CM, Wright M, Pennell CE, Swain J, Doherty DA.
Treatment of periodontal disease during pregnancy: a randomized controlled trial.
Obstet Gynecol 2009; 114: 1239–1248.
30. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical
trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials in Pregnancy
(FOTIP) Team. BJOG 2000; 107: 382–395.
31. Onwude JL, Lilford RJ, Hjartadottir H, Staines A, Tuffnell D. A randomised double
blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol
1995; 102: 95–100.
32. Parazzini F, Benedetto C, Frusca T, Gregorini G, Bocciolone L, Marozio L,
Romero M, Danesino V, De Gaetano G, Gastaldi A, Massobrio M, Remuzzi G,
Tognoni G, Guaschino S, Bianchi C, Valcamonico A, Giambuzzi M, Ammendola D.
Low-dose aspirin in prevention and treatment of intrauterine growth retardation and
pregnancy-induced hypertension. Lancet 1993; 341: 396–400.
33. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, Hayes L, Khazaezadeh N,
Nelson SM, Oteng-Ntim E, Pasupathy D, Patel N, Robson SC, Sandall J, Sanders TA,
Sattar N, Seed PT, Wardle J, Whitworth MK, Briley AL; UPBEAT Trial Consortium.
Effect of a behavioural intervention in obese pregnant women (the UPBEAT study):
a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2015; 3:
767–777.
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